Monday, March 30, 2015

Genetic Technologies (GENE) CEO Eutillio Buccilli Leading Acquisition Discussions With Big Pharma Pfizer (PFE) In Melbourne Predicts Sierra World Equity Review

HEADLINE: Genetic Technologies  (GENE) CEO Eutillio Buccilli Leading Acquisition Discussions With Big Pharma Pfizer (PFE) In Melbourne Predicts Sierra World Equity Review. Shares of GENE finished higher up over 33% at the close of Monday's trading. Look for the official news, when it breaks remember Sierra called this first!

Our Next Publisher Pick To Be Announced Saturday April 11th 2015, Our Last 2 Picks Both More Than Doubled As Did Most Of Our Picks in 2014!

Sierra Returns From Vacation in The US Virgin Islands in 15 days!

Many of our publisher picks rise 100%, 200% or more once they hit the front page of our blog. Get some, sit back and enjoy the ride! Recent big winners include BSTO, XCLL, HHSE, UAPC, AEMD, XTRN, RGMI, PPCH, TSGL, GNPT and RCGP that more than doubled! 
We are vacationing in the US Virgin Islands, check back for our next awesome winning pick when we return.

Follow Sierra on Twitter To Get Our Next Publisher Pick~~Follow Sierra on Twitter

With over 1 million visitors to our blog and thousands of visitors daily, Sierra World Equity Review will be giving MASSIVE MULTIPLE DAY targeted audience exposure to our latest publisher pick

About Sierra World Equity Review

Every day we present our publisher's pick where we profile a stock that our publisher has taken a position in, we believe that the stock is extremely undervalued with potential for significant percentage gains. We also issue short term daily buy or sell ratings with 5 day price targets for stocks in all industries across all markets. 

Sierra World Equity Review and it's publisher have not been compensated to promote any stock but do hold a long position in the stock. We are not affiliated with any executives, owners, brokers, promoters or analysts. The publisher of Sierra World Equity Review is not a registered investment adviser, before making a purchase or sale of any securities featured on this site, we strongly recommend consultation with a registered securities representative. Please remember to do your own due diligence in regards to any stocks that appear on our websites, please read our disclaimer and privacy policy below.